Loading…
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-28M | $-27M | $-28M | -37.9% | - | - |
| 2024 | $0M | $-32M | $-31M | $-35M | -326.3% | - | - |
| 2023 | $0M | $-38M | $-37M | $-37M | 468.2% | -100.0% | - |
| 2022 | $1M | $-32M | $-41M | $-28M | -851.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 1 | 0 | 0 | 0 |
| Cost Of Revenue | 0.10 | 0 | 0 | 0 |
| Gross Profit | 0.90 | 0 | 0 | 0 |
| Operating Expense | 32.85 | 37.87 | 31.51 | 28.27 |
| Operating Income | -31.95 | -37.87 | -31.51 | -28.27 |
| EBITDA | -31.95 | -37.87 | -31.51 | -28.27 |
| EBIT | -31.95 | -37.87 | -31.51 | -28.27 |
| Pretax Income | -41.30 | -37.34 | -30.88 | -26.86 |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -41.30 | -37.34 | -30.88 | -26.86 |
| Net Income Common Stockholders | -41.30 | -37.34 | -30.88 | -26.86 |
| Total Expenses | 32.95 | 37.87 | 31.51 | 28.27 |
| Interest Income | 0.32 | 0.53 | 0.63 | 1.41 |
| Research And Development | 20.27 | 24.01 | 19.10 | 16.02 |
| Selling General And Administration | 12.58 | 13.86 | 12.42 | 12.25 |
| Normalized EBITDA | -22.28 | -37.87 | -31.51 | -28.27 |
| Normalized Income | -31.63 | -37.34 | -30.88 | -26.86 |
| Basic EPS | -2.13 | -1.34 | -0.50 | -0.25 |
| Diluted EPS | -2.13 | -1.34 | -0.50 | -0.25 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | -9.67 | 0 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | -9.67 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -41.30 | -37.34 | -30.88 | -26.86 |
| Reconciled Cost Of Revenue | 0.10 | 0 | 0 | 0 |
| Net Interest Income | 0.32 | 0.53 | 0.63 | 1.41 |
| Net Income From Continuing And Discontinued Operation | -41.30 | -37.34 | -30.88 | -26.86 |
| Total Operating Income As Reported | -41.95 | -37.87 | -31.51 | -28.27 |
| Diluted Average Shares | 19.40 | 27.78 | 61.20 | 109.05 |
| Basic Average Shares | 19.40 | 27.78 | 61.20 | 109.05 |
| Diluted NI Availto Com Stockholders | -41.30 | -37.34 | -30.88 | -26.86 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -41.30 | -37.34 | -30.88 | -26.86 |
| Net Income Continuous Operations | -41.30 | -37.34 | -30.88 | -26.86 |
| Other Income Expense | -9.67 | 0 | 0 | 0 |
| Special Income Charges | -9.70 | 0 | 0 | 0 |
| Other Special Charges | 10 | 0 | 0 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 0 | 0 |
| Restructuring And Mergern Acquisition | -0.30 | 0 | 0 | 0 |
| Gain On Sale Of Security | 0.04 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 0.32 | 0.53 | 0.63 | 1.41 |
| Interest Income Non Operating | 0.32 | 0.53 | 0.63 | 1.41 |
| General And Administrative Expense | 12.58 | 13.86 | 12.42 | 12.25 |
| Other Gand A | 12.58 | 13.86 | 12.42 | 12.25 |
| Operating Revenue | 1 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| SELLAS Life Sciences Group, Inc.this co. | SLS | $862M | - | 10.09 | -37.9% | - |
| Sana Biotechnology, Inc. | SANA | $877M | - | 5.39 | -151.8% | -4.57 |
| LB Pharmaceuticals Inc | LBRX | $877M | - | 2.57 | -8.4% | -20.06 |
| Bright Minds Biosciences Inc. | DRUG | $872M | - | 10.63 | -14.9% | - |
| Talkspace, Inc. | TALK |
| $869M |
| 129.75 |
| 7.39 |
| 6.7% |
| 128.51 |
| Janux Therapeutics, Inc. | JANX | $860M | - | 0.89 | -11.9% | 0.55 |
| EVMN | EVMN | $859M | - | 3.66 | -33.5% | -8.93 |
| Theravance Biopharma, Inc. | TBPH | $859M | 8.09 | 2.87 | 35.7% | -296.42 |
| MannKind Corporation | MNKD | $849M | 137.50 | -16.57 | -11.5% | 19.49 |
| Peer Median | - | 129.75 | 3.26 | -11.7% | -4.57 | |